TOBRASONE
LOE Approachingfluorometholone acetate; tobramycin
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jul 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TOBRASONE (fluorometholone acetate; tobramycin) is clinical pharmacology corticosteroids suppress the inflammatory response to inciting agents of mechanical, chemical or immunological nature. First approved in 1989.
Drug data last refreshed 6h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBRASONE is a fixed-dose ophthalmic suspension combining fluorometholone acetate (a corticosteroid) and tobramycin (an aminoglycoside antibiotic) for topical eye use. It suppresses inflammatory response while providing broad-spectrum antimicrobial coverage for bacterial ocular infections. The corticosteroid component reduces inflammation and IOP rise risk relative to stronger agents like dexamethasone.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating shrinking team investment and transition focus toward cost-containment and generic transition strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to inciting agents of mechanical, chemical or immunological nature. No generally accepted explanation of this steroid property has been advanced. Corticosteroids cause a rise in intraocular pressure (IOP) in susceptible…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TOBRASONE offers limited upside growth opportunity given its LOE-approaching status and zero linked job openings, making it a transition or defensive career move rather than a growth opportunity. Professionals on this team should expect organizational restructuring, focus on cost management, and potential transition to generic product stewardship or adjacent therapeutic areas.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.